Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.…
DMAADrugs Made In America Acquisition Corp.10.90USD0.00%
About Drugs Made In America Acquisition (NASDAQ: DMAA)
›
Drugs Made In America Acquisition (NASDAQ: DMAA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Shell Companies industry, part of the Financial Services sector.
The shares were at 10.90 USD on 20 November 2026, up 5.6% over 52 weeks. Its 52-week range is 10.32 USD to 10.91 USD, and it trades at the top of that range.
At a market capitalisation of 264.62M USD, it trades at 64.1 times trailing earnings. The median trailing P/E of its 5 largest Shell Companies peers is 36.0, a premium of 78% for DMAA.
Drugs Made In America Acquisition reports return on equity of 2.6% and an operating margin of 0.0%.
Its debt exceeds its cash by 407.99K USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.